Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Generic Sweden AB (publ) on the sale of Generic Systems Sweden AB
Mandate

Vinge advises Generic Sweden AB (publ) on the sale of Generic Systems Sweden AB

June 21, 2017

Vinge advises Generic Sweden AB (publ), which is listed on First North, in connection with the sale of its consultancy business Generic Systems Sweden AB to MSC Group AB (publ). 

Generic Sweden's divestment of the consultancy business focuses the group's operations towards telecom. The purchase price consists of a cash component and shares in MSC Group AB (publ), which is listed on Nasdaq OMX Stockholm Small Cap.

The Vinge team advising Generic Sweden includes partners Jesper Ottergren (M&A) and Erik Sjöman (Capital Markets).

Related

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its rights issue

 Vinge has advised Vicore Pharma Holding AB (publ) in connection with an oversubscribed rights issue of shares whereby Vicore receives issue proceeds of approximately SEK 782 million before deduction of transaction costs.
October 22, 2024

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its directed share issue

 Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore receives issue proceeds of approximately SEK 100 million before deduction of transaction costs.
October 22, 2024

Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS

 Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS. The proceedings, which included considerations regarding state aid approved by the European Commission, have among other things involved restructuring, debt write-downs as well as an investment by a consortium consisting of Castlelake, Air France-KLM, Lind Invest and the Danish state. In total, the investment amounted to approximately USD 1.2 billion in SAS, divided into USD 475 million in unlisted equity and USD 725 million in convertible debt.
October 21, 2024